nach oben

Erschienen in:

03.10.2016 | Original Article

Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine

verfasst von: Soheila Moeini, Mohsen Saeidi, Fatemeh Fotouhi, Mahdieh Mondanizadeh, Sadegh Shirian, Alireza Mohebi, Ali Gorji, Amir Ghaemi

Erschienen in: Archives of Virology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The use of DNA vaccines has become an attractive approach for generating antigen-specific cytotoxic CD8⁺ T lymphocytes (CTLs), which can mediate protective antitumor immunity. The potency of DNA vaccines encoding weakly immunogenic tumor-associated antigens (TAAs) can be improved by using an adjuvant injected together with checkpoint antibodies. In the current study, we evaluated whether the therapeutic effects of a DNA vaccine encoding human papilloma virus type 16 (HPV-16) E7 can be enhanced by combined application of an immune checkpoint blockade directed against the programmed death-1 (PD-1) pathway and secondary lymphoid tissue chemokine (SLC) also known as CCL21 adjuvant, in a mouse cervical cancer model. The therapeutic effects of the DNA vaccine in combination with CCL21 adjuvant plus PD-1 blockade was evaluated using a tumor growth curve. To further investigate the mechanism underlying the antitumor response, cytolytic and lymphocyte proliferation responses in splenocytes were measured using non-radioactive cytotoxicity and MTT assays, respectively. Vascular endothelial growth factor (VEGF) and IL-10 expression in the tumor and the levels of IFN-γ and IL-4 in supernatants of spleno-lymphocyte cultures were measured using ELISA. The immune efficacy was evaluated by in vivo tumor regression assay. The results showed that vaccination with a DNA vaccine in combination with the CCL21 adjuvant plus PD-1 blockade greatly enhanced cytotoxic T lymphocyte production and lymphocyte proliferation rates and greatly inhibited tumor progression. Moreover, the vaccine in combination with adjuvant and blockade significantly reduced intratumoral VEGF, IL-10 and splenic IL-4 but induced the expression of splenic IFN-γ. This formulation could be an effective candidate for a vaccine against cervical cancers and merits further investigation.

Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H (2014) DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice. J Virol Methods 206:12–18CrossRefPubMed

Bobanga ID, Petrosiute A, Huang AY (2013) Chemokines as cancer vaccine adjuvants. Vaccines 1:444–462PubMed

Bos R, Marquardt KL, Cheung J, Sherman LA (2012) Functional differences between low-and high-affinity CD8+ T cells in the tumor environment. Oncoimmunology 1:1239–1247CrossRefPubMedPubMedCentral

Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I (2016) Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer immunology, immunotherapy : CII

Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM (2015) Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide. J Virol 89:10680–10687CrossRefPubMedPubMedCentral

Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceed Nat Acad Sci USA 107:4275–4280CrossRef

Drake C (2012) Combination immunotherapy approaches. Ann Oncol 23:viii41–viii46

Dubinett SM, Lee JM, Sharma S, Mule JJ (2010) Chemokines: can effector cells be redirected to the site of the tumor? Cancer journal (Sudbury, Mass) 16:325-335

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:3591–3603CrossRefPubMedPubMedCentral

10.

Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS (2005) Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β–inducible gene expression, without significant toxicity. Blood 105:489–495CrossRefPubMed

11.

Gableh F, Saeidi M, Hemati S, Hamdi K, Soleimanjahi H, Gorji A, Ghaemi A (2016) Combination of the toll like receptor agonist and alpha-Galactosylceramide as an efficient adjuvant for cancer vaccine. J Biomed Sci 23:16CrossRefPubMedPubMedCentral

12.

Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, Ebtekar M (2007) Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. Comp Immunol Microbiol Infect Dis 30:197–210CrossRefPubMed

13.

Ghaemi A, Soleimanjahi H, Gill P, Hassan ZM, Razeghi S, Fazeli M, Razavinikoo SM (2011) Protection of mice by a lambda-based therapeutic vaccine against cancer associated with human papillomavirus type 16. Intervirology 54:105–112CrossRefPubMed

14.

He J, Hu Y, Hu M, Li B (2015) Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 5

15.

Hong C, Lee HJ, Kim HJ, Lee JJ (2014) The Lymphoid Chemokine CCL21 Enhances the Cytotoxic T Lymphocyte-Inducing Functions of Dendritic Cells. Scand J Immunol 79:173–180CrossRefPubMed

16.

Huang Z, Peng S, Knoff J, Lee SY, Yang B, Wu TC, Hung CF (2015) Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model. J Biomed Sci 22

17.

Ji M, Liu Y, Li Q, Li X-D, Zhao W-Q, Zhang H, Zhang X, Jiang J-T, Wu C-P (2015) PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of translational medicine 13:1CrossRef

18.

Jin H-T, Ahmed R, Okazaki T (2010) Role of PD-1 in regulating T-cell immunity. Negative Co-Receptors and Ligands. Springer, pp 17–37

19.

Kirk CJ, Hartigan-O’Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, Mule JJ (2001) T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61:2062–2070PubMed

20.

Kyi C, Postow MA (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588:368–376CrossRefPubMed

21.

Lin K, Roosinovich E, Ma B, Hung CF, Wu TC (2010) Therapeutic HPV DNA vaccines. Immunol Res 47:86–112CrossRefPubMedPubMedCentral

22.

Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X (2014) Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Trans Med 12:36CrossRef

23.

Ma B, Xu Y, Hung C-F, Wu T-C (2010) HPV and therapeutic vaccines: where are we in 2010? Curr Cancer Therapy Rev 6:81–103CrossRef

24.

McGray AJ, Bernard D, Hallett R, Kelly R, Jha M, Gregory C, Bassett JD, Hassell JA, Pare G, Wan Y, Bramson JL (2012) Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology 1:419–431CrossRefPubMedPubMedCentral

25.

Mittal SK, Roche PA (2015) Suppression of antigen presentation by IL-10. Curr Opin Immunol 34:22–27CrossRefPubMedPubMedCentral

26.

Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN (2011) Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Euro J Immunol 41:2977–2986CrossRef

27.

Müller D (2015) Antibody fusions with immunomodulatory proteins for cancer therapy. Pharmacol Ther 154:57–66CrossRefPubMed

28.

Naderi M, Saeedi A, Moradi A, Kleshadi M, Zolfaghari MR, Gorji A, Ghaemi A (2013) Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virologica Sinica 28:167–173CrossRefPubMed

29.

Nagato T, Lee YR, Harabuchi Y, Celis E (2014) Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res Off J Am Assoc Cancer Res 20:1223–1234CrossRef

30.

Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed MS, Pham-Duc M, Vu MD, Lipp M, Dorken B, Pezzutto A, Westermann J (2012) CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Therapy 19:69–76CrossRefPubMed

31.

Nguyen-Hoai T, Pham-Duc M, Gries M, Dörken B, Pezzutto A, Westermann J (2016) CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model. Cancer Gene Therapy

32.

Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A (2014) Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 153:145–152CrossRefPubMed

33.

Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG (2015) PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res 3:946–955CrossRefPubMedPubMedCentral

34.

Riedl K, Baratelli F, Batra RK, Yang S, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S (2003) Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer 2:1CrossRef

35.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA (2009) Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 8:1761–1771CrossRefPubMed

36.

Rosales R, Rosales C (2014) Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol 5:1002CrossRefPubMedPubMedCentral

37.

Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ (2012) Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012:656340CrossRefPubMedPubMedCentral

38.

Saade F, Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11:189–209CrossRefPubMedPubMedCentral

39.

Sajadian A, Tabarraei A, Soleimanjahi H, Fotouhi F, Gorji A, Ghaemi A (2014) Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol 159:1951–1960CrossRefPubMed

40.

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187–2194CrossRefPubMedPubMedCentral

41.

Schmitz V, Vilanueva H, Raskopf E, Hilbert T, Barajas M, Dzienisowicz C, Gorschlüter M, Strehl J, Rabe C, Sauerbruch T (2006) Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Therapy 13:1198–1205CrossRefPubMed

42.

Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol (Baltimore, Md : 1950) 164:4558–4563

43.

Sharon E, Streicher H, Goncalves P, Chen HX (2014) Immune checkpoints in cancer clinical trials. Chinese Journal of Cancer 33:434–444CrossRefPubMedPubMedCentral

44.

Shi L, Chen S, Yang L, Li Y (2013) The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 6:74CrossRefPubMedPubMedCentral

45.

Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, Moradi A, Atyabi F, Kelishadi M (2014) Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. J Biomed Sci 21:69CrossRefPubMedPubMedCentral

46.

Tolba KA, Bowers WJ, Muller J, Housekneckt V, Giuliano RE, Federoff HJ, Rosenblatt JD (2002) Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res 62:6545–6551PubMed

47.

Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nature Rev Cancer 12:237–251CrossRef

48.

Vezys V, Penaloza-MacMaster P, Barber DL, Ha SJ, Konieczny B, Freeman GJ, Mittler RS, Ahmed R (2011) 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol (Baltimore, Md : 1950) 187:1634–1642

49.

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HS (2015) Immune evasion in cancer: Mechanistic basis and therapeutic strategies. In: Seminars in Cancer Biology. Elsevier, pp S185–S198

50.

Waldmann TA (2006) Effective cancer therapy through immunomodulation. Ann Rev Med 57:65–81CrossRefPubMed

51.

Yang MC, Yang A, Qiu J, Yang B, He L, Tsai YC, Jeang J, Wu TC, Hung CF (2016) Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8⁺ T-cell immune responses and antitumor effects without adjuvant. Cell Biosci 6

Titel: Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine
verfasst von: Soheila Moeini
Mohsen Saeidi
Fatemeh Fotouhi
Mahdieh Mondanizadeh
Sadegh Shirian
Alireza Mohebi
Ali Gorji
Amir Ghaemi
Publikationsdatum: 03.10.2016
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 2/2017
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-016-3091-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Erratum to: Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine

Molecular identification of a new begomovirus infecting yellow passion fruit (Passiflora edulis) in Colombia

Rabies vaccine development by expression of recombinant viral glycoprotein

Isolation and characterization of a new enterovirus F in yak feces in the Qinghai-Tibetan Plateau

A sensitive one-step TaqMan amplification approach for detection of rubella virus clade I and II genotypes in clinical samples

Genome sequence of a porcine circovirus-like virus P1 mutant in China

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin